How we’re leveraging our technology to help find solutions for the long-term impact of COVID-19

About Caladrius

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease.

News

November 17, 2020
Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer

November 10, 2020
Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020

November 5, 2020
Caladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial Results

Events

November 13, 2020
American Heart Association’s Scientific Sessions 2020

November 5, 2020
Caladrius Biosciences Third Quarter 2020 Financial Results and Business Update Conference Call

September 1, 2020
LD Micro 500 Virtual Conference

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

LD Micro 500 Virtual Conference

CD34 Cell Technology

LD Micro 500 Virtual Conference

T Regulatory Cell Technology